Mark C Wiggins
CIK 1236540 · Chief Business Officer · last filed 2022-03-09
Mark C Wiggins is a Chief Business Officer who has filed 48 SEC Form 4 insider transactions across 3 companies since 2007. Across all open-market trades the lifetime net is −$24.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.5M across reported positions. 47 SEC filings were submitted jointly with BIOGEN INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BIIB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Tracon Pharmaceuticals, Inc. (TCON) Delisted | Chief Business Officer | 685 | $0.03 | $22 | $59.6K | 6 | 2022-02-01 |
| ZOGENIX, INC. (ZGNX) Delisted | Director | 2,500 | $26.68 | $66.7K | -$261.3K | 13 | 2021-05-28 |
| BIIB | EVP Corp. and Bus. Dev. | 23,457 | $233.48 | $5.48M | -$24.01M | 27 | 2008-09-29 |
Recent Filings
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-03-09 | — | Mixed | −2,500 | $0 | |
| 2022-02-01 | Tracon Pharmaceuticals, Inc. (TCON) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-28 | ZOGENIX, INC. (ZGNX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-02 | Tracon Pharmaceuticals, Inc. (TCON) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-12-30 | Tracon Pharmaceuticals, Inc. (TCON) Delisted | Buy (P) | +1,000 | $10.6K | EDGAR |
| 2020-09-14 | Tracon Pharmaceuticals, Inc. (TCON) Delisted | Buy (P) | +7,000 | $29.0K | EDGAR |
| 2020-06-29 | ZOGENIX, INC. (ZGNX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-03-24 | ZOGENIX, INC. (ZGNX) Delisted | Buy (P) | +2,500 | $51.2K | EDGAR |
| 2020-02-04 | Tracon Pharmaceuticals, Inc. (TCON) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-01-24 | Tracon Pharmaceuticals, Inc. (TCON) Delisted | Buy (P) | +5,000 | $20.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.